2016 Fiscal Year Final Research Report
Significance of CIMP as a biomarker for chemotherapy in colorectal cancer
| Project/Area Number |
26460958
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
ZHANG XIAFEI 東北大学, 大学院生
SOEDA HIROSHI 東北大学, 大学院生
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | CpG アイランド / メチル化 / がん薬物療法 / バイオマーカー |
|---|
| Outline of Final Research Achievements |
The CpG island methylator phenotype (CIMP) with multiple promoter methylated loci has been observed in a subset of human colorectal cancer (CRC) cases. CIMP status, which is closely associated with specific clinicopathological and molecular characteristics, is considered a potential predictive biomarker for efficacy of cancer treatment. The progression-free survival of patients with CIMP-positive tumors receiving sequential therapy with FOLFOX as the first-line treatment followed by irinotecan-based therapy as the second-line treatment was inferior to that of such patients receiving the reverse sequence. Furthermore, CIMP-positive tumors showed higher mutation frequencies for the five EGFR-related genes than the CIMP-negative tumors did. Among the KRAS wild-type tumors, CIMP-positive tumors were associated with a worse clinical outcome than CIMP-negative tumors following anti-EGFR antibody therapy.
|
| Free Research Field |
腫瘍学
|
